



NDA 021260/016

**SUPPLEMENT APPROVAL**

King Pharmaceuticals, LLC  
C/O Pfizer, Inc  
235 East 42<sup>nd</sup> St, Building 219-8-24  
New York, NY, 10017

Attention: Lisa Malandro  
Director, Pfizer Worldwide Regulatory Strategy

Dear Ms. Malandro:

Please refer to your Supplemental New Drug Application (sNDA) dated August 26, 2011, received August 29, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for AVINZA (morphine sulfate extended-release) 30 mg, 45 mg, 60 mg, 75 mg, 90 mg, and 120 mg Capsules.

This prior approval supplement application proposes conversion of the content of the currently approved package insert into the Physicians Labeling Rule (PLR) format as set forth under 21 CFR 201.56 and 21 CFR 201.57.

We have completed our review of this supplemental application, and it is approved effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

Please also refer to your sNDA (S-015), dated August 15, 2011, which provides for the Extended-Release/Long Acting (ER/LA) Opioid Class REMS. With that effort, the package inserts for all ER/LA opioids with a pain indication have been standardized and revised to current standards. The revisions derived from both sNDAs have been combined in the attached approved labeling.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the

patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

### **PROMOTIONAL MATERIALS**

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Christopher Hilfiger, Regulatory Project Manager, at (301) 796-4131.

Sincerely,

*{See appended electronic signature page}*

Bob A. Rappaport, MD  
Director  
Division of Anesthesia, Analgesia,  
and Addiction Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JUDITH A RACOOSIN on behalf of BOB A RAPPAPORT  
07/09/2012